BetterLife Engages Canadian Healthcare Investment Firm, Aims For Clinical Trial Programs

Zinger Key Points
  • The Vancouver-based company expects the agreement to help advance its clinical trial initiatives.
  • Both the synthetic route and the end product are novel developments.

BetterLife Pharma BETRF, a non-hallucinogenic psychedelics biotech company, has contracted Bloom Burton Securities Inc. for strategic advisory services.

“Canada’s leading healthcare investment banking firm” holds “extensive understanding” of the overall biotechnology and healthcare landscape and the emerging psychedelics space in particular, CEO Ahmad Doroudian said of Bloom Burton.

The Vancouver-based company expects the agreement to help advance its clinical trial initiatives.

See Also: EXCLUSIVE - Defining 'Natural' Psychedelics, State Regulations & Ayahuasca's Benefits

Throughout 2022, BetterLife achieved several goals. One of them was manufacturing a kg-sized batch of its proprietary 2-bromo-LSD synthetic compound BETR-001, plus having initiated Good Manufacturing Practices (GMP)-compliant manufacturing.

The raw material, as well as the synthetic production pathway, do not involve controlled substances. Therefore, they are not bound to regulations and would allow for self-administration.

Both the synthetic route and the end product are novel developments for which the company has provisional patents.

2022’s preclinical trials progress included an in-vitro and in-vivo characterization of BETR-001; more specifically, the in-vitro pharmacological profiling considering key neuroreceptors in comparison to parent compound LSD, as well as in-vivo studies showing the non-hallucinogenic profile and effective structural neuroplasticity and anti-depressant profile.

The research provided insight on BETR-001’s activity and the pharmacological differences with LSD which could translate into therapeutic benefits and, based on these positive findings, BetterLife has begun IND-enabling toxicology studies.

IP-wise, the company has filed both international PCT and US patent applications for LSD derivatives (including 2-bromo-LSD) covering the composition of matter, synthesis, and use for the treatment of a range of conditions including depression, anxiety, PTSD and neuropathic pain.

Photo by Girl with red hat on Unsplash

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksPsychedelicsGuidanceContractsLegalManagementTop StoriesMarketsAdvisoryBloom BurtonNext-Generation PsychedelicsNon-Hallucinogenic Psychedelic CompoundPsychedelic-Assisted Therapies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.